NCT00828854 - Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2008

Primary Completion Date

November 24, 2009

Study Completion Date

November 24, 2009

Conditions

ER+ Breast Cancer

Interventions

DRUG

Entinostat

Entinostat 5 mg PO every week

DRUG

Aromatase Inhibitor (AI) Therapy

AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.

Trial Locations (6)

Unknown

St. Vincent's University Hospital, Dublin

The University of Birmingham, Birmingham

Velindre Hospital - Whitchurch, Cardiff

Whiston Hospital; Clatterbridge Centre for Oncology, Liverpool

University College London Hospitals, London

Christie Hospital, Manchester Breast Centre, Manchester